Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses | ||
| Cost of goods sold | 6,323 | 5,028 |
| Research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Total operating expenses | 62,668 | 51,931 |
| Income from operations | 53,689 | 36,252 |
| Other income | ||
| Interest and other income, net | 7,753 | 7,345 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s SG&A?
- Krystal Biotech, Inc. (KRYS) reported SG&A of $41.01M in Q1 2026.
- How has Krystal Biotech, Inc.'s SG&A changed year-over-year?
- Krystal Biotech, Inc.'s SG&A increased by 25.6% year-over-year, from $32.65M to $41.01M.
- What is the long-term trend for Krystal Biotech, Inc.'s SG&A?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s SG&A has grown at a 22.2% compound annual growth rate (CAGR), from $98.29M to $146.83M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Krystal Biotech, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude